Paclitaxel
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Paclitaxel: From Antineoplastic Chemotherapy to Female Breast Carcinoma
One-Sentence Summary
Paclitaxel is a taxane-class antineoplastic agent already used worldwide as standard-of-care chemotherapy for multiple solid tumors. The TxGNN model's top prediction — Female Breast Carcinoma — is supported by 13 clinical trials and 20 publications, though this reflects an already well-established global oncology use rather than a novel biological hypothesis; the main gap is that paclitaxel is currently not marketed in New Zealand.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from local regulatory records (drug is not marketed in New Zealand; no license data on file) |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data from DrugBank/TFDA has not been retrieved (see Data Gap DG002). Based on available evidence in this pack, paclitaxel is a taxane that binds β-tubulin to stabilize microtubules and block spindle disassembly, driving G2/M cell-cycle arrest and apoptosis. This is a well-documented cytotoxic mechanism, not a new hypothesis.
Importantly, the trial and literature evidence base for "female breast carcinoma" does not represent a genuinely novel repurposing signal — paclitaxel (and albumin-bound paclitaxel) is already a globally established, guideline-recommended chemotherapy backbone for breast cancer, frequently combined with trastuzumab, lapatinib, or other targeted agents. The TxGNN model's high score most likely reflects this pre-existing, extensively documented drug-disease relationship rather than an untested mechanistic bridge.
The practical significance of this candidate is therefore primarily regulatory: paclitaxel is not currently marketed in New Zealand for any indication, so the "new indication" opportunity here is a market-access question (registration/import pathway) rather than a scientific discovery question. Any evaluation should treat this distinction explicitly when deciding next steps.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00003992 | Phase 2 | Completed | 200 | Paclitaxel + trastuzumab adjuvant therapy in HER2-overexpressing stage II/IIIA breast cancer |
| NCT00281658 | Phase 3 | Completed | 444 | Lapatinib + paclitaxel vs. placebo + paclitaxel in ErbB2-amplified metastatic breast cancer; direct efficacy data |
| NCT00455533 | Phase 2 | Completed | 384 | Randomized biomarker study comparing sequential AC→ixabepilone vs. AC→paclitaxel in early-stage breast cancer |
| NCT02280252 | Phase 2 | Completed | 69 | Concurrent paclitaxel and radiation in locally advanced breast cancer, multiethnic cohort |
| NCT00272987 | Phase 3 | Terminated | 63 | Paclitaxel + trastuzumab + lapatinib vs. paclitaxel + trastuzumab + placebo in ErbB2+ metastatic breast cancer |
| NCT04753177 | Phase 2/3 | Unknown | 120 | Neoadjuvant combined hormone therapy in premenopausal ER+/HER2- locally advanced breast cancer |
| NCT00054028 | Phase 1/2 | Completed | 31 | Suramin combined with paclitaxel in advanced (stage IIIB/IV) metastatic breast cancer |
| NCT00544167 | N/A | Completed | 45 | Adjuvant doxorubicin/cyclophosphamide followed by paclitaxel + sorafenib in high-risk early-stage breast cancer |
| NCT02225652 | Phase 2 | Completed | 11 | Dose-dense FEC followed by weekly paclitaxel in primary breast cancer |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31783552 | 2019 | Review | Biomolecules | Overview of paclitaxel's mechanistic and clinical effects in breast cancer, including resistance mechanisms |
| 9282422 | 1997 | Review | Drug and Therapeutics Bulletin | Early review of paclitaxel/docetaxel licensing extension to metastatic breast carcinoma |
| 11147586 | 2000 | Cohort | Cancer | Phase II trial of doxorubicin + paclitaxel in advanced breast carcinoma; importance of prior anthracycline exposure |
| 32461977 | 2020 | Cohort | BioMed Research International | Real-world efficacy of neoadjuvant epirubicin/cyclophosphamide + weekly paclitaxel/trastuzumab in HER2+ breast carcinoma |
| 39317691 | 2024 | Preclinical | Chemical Biology & Drug Design | Paclitaxel combination therapeutic potential and in vivo biomarkers in breast carcinoma |
| 39009452 | 2024 | Preclinical | Journal for ImmunoTherapy of Cancer | Paclitaxel's effect on tumor-associated macrophages enhancing PD-1 blockade in breast cancer |
| 20665703 | 2011 | Preclinical | Journal of Cellular Physiology | ZD6474 enhances paclitaxel antiproliferative/apoptotic effects in breast carcinoma cells |
| 31515668 | 2019 | Preclinical/in vitro | Cancer Chemotherapy and Pharmacology | SRSF3 downregulation sensitizes breast cancer cells to paclitaxel treatment |
| 24823476 | 2014 | Preclinical/Genetic | Nature Communications | TEKT4 germline variations enriched in breast cancer resistant to paclitaxel |
| 17272681 | 2007 | Preclinical | Molecular Pharmacology | Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in breast carcinoma cells |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (taxane class — microtubule-stabilizing agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions (TFDA insert not yet retrieved — see Data Gap DG001) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Standard cytotoxic drug handling precautions apply, consistent with taxane-class chemotherapy agents |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 2 and Phase 3 trials (e.g., NCT00003992, NCT00281658, NCT00455533) support paclitaxel's efficacy in breast cancer, and this use is already globally established rather than experimental. However, New Zealand-specific regulatory and safety data are absent, and the drug is currently unmarketed there, so guardrails are needed before any local deployment decision.
To proceed, the following is needed:
- TFDA/Medsafe package insert with warnings, precautions, and contraindications (Blocking gap, DG001)
- DrugBank-sourced mechanism of action detail to confirm mechanistic relevance (High priority gap, DG002)
- Formal drug-drug interaction (DDI) query, currently returning "not found"
- Assessment of the New Zealand registration/import pathway given zero current authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.